Based on HIF-1α/Wnt/β-Catenin Pathway to Explore the Effect of Qingshen Granules on Chronic Renal Failure Patients: A Randomized Controlled Trial

• Published in: Evidence-based complementary and alternative medicine Vol. 2019; no. 2019; pp. 1 - 7
• Main Authors: Wang, Dong, Jin, Hua, Zhang, Lei, Wang, Yiping
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2019; Hindawi; John Wiley & Sons, Inc
• Subjects: Alternative medicine; Clinical trials; Creatinine; E-cadherin; Epidermal growth factor receptors; Evidence-based medicine; Glomerular filtration rate; Hypoxia; Kidney diseases; Medical research; Oxidative stress; Patients; Physiology; Renal failure; Renal function; Renal replacement therapy; Serum levels; Signal transduction; Statistical analysis; Traditional Chinese medicine; Wnt protein; β-Catenin; United States > US; China
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2019/7656105

Objectives. This study investigates the effect of Qingshen Granules (QSG) on chronic renal failure patients and the HIF-1α/Wnt/β-catenin signaling pathway. Methods. Subjects were randomly divided into treatment and control groups, with 42 patients in each group. Participants in the treatment group received 10 g oral doses of QSG 3 times a day, for 12 weeks, whereas subjects in the control group were given a placebo. The effective rates of traditional Chinese medicine (TCM) symptom, serum creatinine (Scr), and estimate glomerular filtration rate (eGFR) as well as the serum levels of HIF-1α, Wnt1, β-catenin, α-SMA, and E-cadherin were evaluated. Results. Eighty patients completed the treatment program and two dropped out. After 12 weeks, the effective rates of TCM symptom and eGFR were found to be higher in the treatment group than in the control group, with statistically significant differences (P = 0.024 and 0.019, respectively). Meanwhile, lower levels of HIF-1α, Wnt1, β-catenin, α-SMA, and E-cadherin were detected in the treatment group, and the differences were statistically significant (P ≤ 0.001, P = 0.001, P ≤ 0.001, P ≤ 0.001, and P = 0.039). No adverse events occurred during the study. Conclusions. QSG can alleviate the clinical symptoms of chronic renal failure (CRF) and protect renal function in patients by influencing the HIF-1α/Wnt/β-catenin signaling pathway. The treatment exhibits no adverse effects and is thus safe to be used by humans.